Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Change In Receivables : ¥0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Change In Receivables?

Tianjin Pharmaceutical Da Ren Tang Group's change in receivables for the quarter that ended in Mar. 2024 was ¥0 Mil. It means Tianjin Pharmaceutical Da Ren Tang Group's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Tianjin Pharmaceutical Da Ren Tang Group's change in receivables for the fiscal year that ended in Dec. 2023 was ¥74 Mil. It means Tianjin Pharmaceutical Da Ren Tang Group's Accounts Receivable declined by ¥74 Mil from Dec. 2022 to Dec. 2023 .

Tianjin Pharmaceutical Da Ren Tang Group's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥2,587 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Tianjin Pharmaceutical Da Ren Tang Group's Days Sales Outstanding for the three months ended in Mar. 2024 was 113.18.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Tianjin Pharmaceutical Da Ren Tang Group's liquidation value for the three months ended in Mar. 2024 was ¥1,117 Mil.

Tianjin Pharmaceutical Da Ren Tang Group Change In Receivables Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Change In Receivables Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-102.70

-113.81

-42.07

-732.29

74.01

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Tianjin Pharmaceutical Da Ren Tang Group Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Tianjin Pharmaceutical Da Ren Tang Group's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2586.844	/	2085.588	*	91
=	113.18

2. In Ben Graham's calculation of liquidation value, Tianjin Pharmaceutical Da Ren Tang Group's accounts receivable are only considered to be worth 75% of book value:

Tianjin Pharmaceutical Da Ren Tang Group's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2457.615	-	4022.895	+	0.75 * 2586.844	+	0.5 * 1483.364
=	1,117

Tianjin Pharmaceutical Da Ren Tang Group Change In Receivables Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) » Definitions » Change In Receivables

Traded in Other Exchanges

T14:Singapore

Address

No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193

Website

http://www.jydrt.com.cn

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Headlines

No Headlines